Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) EBIT (2016 - 2025)

Historic EBIT for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$1.2 million.

  • Alaunos Therapeutics' EBIT fell 321.74% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year increase of 6607.81%. This contributed to the annual value of -$4.8 million for FY2024, which is 8595.73% up from last year.
  • Alaunos Therapeutics' EBIT amounted to -$1.2 million in Q3 2025, which was down 321.74% from -$1.0 million recorded in Q2 2025.
  • Alaunos Therapeutics' EBIT's 5-year high stood at -$755000.0 during Q4 2024, with a 5-year trough of -$22.6 million in Q2 2021.
  • Moreover, its 5-year median value for EBIT was -$8.1 million (2022), whereas its average is -$7.4 million.
  • Per our database at Business Quant, Alaunos Therapeutics' EBIT tumbled by 2167.58% in 2021 and then surged by 9050.19% in 2024.
  • Over the past 5 years, Alaunos Therapeutics' EBIT (Quarter) stood at -$11.1 million in 2021, then rose by 22.89% to -$8.5 million in 2022, then increased by 6.71% to -$7.9 million in 2023, then surged by 90.5% to -$755000.0 in 2024, then plummeted by 57.22% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$1.0 million for Q2 2025, and -$1.1 million during Q1 2025.